Athena Papas

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Simon Bowman, Robert I. Fox, Thomas Dörner et al. · The Lancet · 2021 · 201 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +12

Treatment of primary sjögren's syndrome with low‐dose human interferon alfa administered by the oromucosal route: Combined phase III results

Martin J. Cummins, Athena Papas, Gary M. Kammer et al. · Arthritis Care & Research · 2003 · 145 citations

The effects of denture status on nutrition

Athena Papas, Carole A. Palmer, Maureen C. Rounds et al. · Special Care in Dentistry · 1998 · 134 citations

Nutrition, Dental Conditions, Body Composition +14

Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine

Athena Papas, Yvonne S. Sherrer, Michael W. Charney et al. · JCR Journal of Clinical Rheumatology · 2004 · 127 citations

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng et al. · The Lancet Rheumatology · 2020 · 113 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +14